Spectrum Pharmaceuticals, Inc. - SPPI STOCK NEWS

Spectrum Pharmaceuticals is set to engage investors through two upcoming presentations at major healthcare conferences in New York. The Jefferies Healthcare Conference will feature a fireside chat on June 9, 2022, from 1 to 1:25 p.m. ET, followed by a presentation at the JMP Securities Life Sciences Conference on June 16, 2022, from 9 to 9:25 a.m. ET. Both events will be accessible via live webcast on the company’s Investor Relations webpage. Spectrum focuses on developing innovative oncology therapies, with a late-stage pipeline designed to meet significant medical needs.

Spectrum Pharmaceuticals announced promising data for poziotinib, targeting advanced non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations. The findings, presented at the 2022 ASCO Annual Meeting, indicate that reduced circulating tumor DNA (ctDNA) levels correlate with tumor shrinkage in responding patients. Poziotinib, which has received Fast Track designation from the FDA, is under review with a Prescription Drug User Fee Act (PDUFA) date of November 24, 2022. The data suggests ctDNA reduction may predict treatment response.

Spectrum Pharmaceuticals (NASDAQ: SPPI) has announced its participation in the upcoming H.C. Wainwright Global Investment Conference, scheduled for May 23-26, 2022, in Miami Beach and virtually. A presentation will be accessible on the company's Investor Relations webpage starting May 24, 2022, at 7:00 a.m. ET. The company specializes in targeted oncology therapies and boasts a robust pipeline aimed at addressing unmet medical needs. Spectrum emphasizes its commitment to developing and commercializing innovative treatments in the biopharmaceutical sector.

Spectrum Pharmaceuticals (NasdaqGS: SPPI) has announced its financial results for Q1 2022, revealing a net loss of $15.4 million, or $0.09 per share, a significant improvement from the $35.7 million loss in Q1 2021. The FDA has accepted the resubmitted BLA for eflapegrastim, with a PDUFA date set for September 9, 2022, alongside an NDA for poziotinib under review due by November 24, 2022. Poziotinib shows promising results in treating NSCLC patients with HER2 mutations. The company concludes the quarter with approximately $89.2 million in cash, aiming to extend its runway into 2023.

Spectrum Pharmaceuticals (NASDAQ: SPPI) announced the appointment of Nora Brennan as Chief Financial Officer, effective May 25, 2022. Ms. Brennan, previously a board member and audit committee chair since December 2020, replaces her board responsibilities to focus on her new role. CEO Tom Riga highlighted her strong background in finance and experience in advancing clinical programs. Prior to Spectrum, Brennan served as CFO at Fore Biotherapeutics and TELA Bio, guiding successful IPOs and financing strategies. Brittany Bradrick will take over as Chairperson of the Audit Committee.

Spectrum Pharmaceuticals (NASDAQ: SPPI) announced a conference call on May 12, 2022, at 4:30 p.m. ET to discuss Q1 2022 financial results and provide a corporate update. Investors can participate via phone or through the company’s website. Spectrum focuses on acquiring and developing innovative oncology therapies, boasting a promising late-stage pipeline designed to address unmet medical needs.

Spectrum Pharmaceuticals (NASDAQ: SPPI) has appointed Brittany Bradrick to its Board of Directors, bringing 25 years of finance and corporate development experience. Her track record in M&A and the life sciences sector is expected to enhance the board's impact as the company moves forward.

Bradrick's leadership comes at a pivotal time with two product candidates under FDA review, indicating potential commercialization. Chairman William Ashton expressed confidence in her ability to contribute to Spectrum's mission of delivering innovative cancer treatments.

Spectrum Pharmaceuticals (SPPI) announced the FDA has accepted its resubmitted Biologics License Application (BLA) for eflapegrastim, with a PDUFA date of September 9, 2022. This novel G-CSF aims to reduce febrile neutropenia in patients undergoing myelosuppressive chemotherapy for non-myeloid malignancies. Supported by data from two Phase 3 trials (ADVANCE and RECOVER) involving 643 patients, eflapegrastim demonstrated non-inferiority to pegfilgrastim in managing severe neutropenia. The potential approval is seen as a significant step in Spectrum's regulatory journey.

Spectrum Pharmaceuticals (NASDAQ: SPPI) announced the acceptance of an abstract for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 8-13, 2022 in New Orleans. The presentation, titled Predictive ability of circulating tumor DNA by Guardant360 in poziotinib-treated patients, will occur on April 12, 2022, showcasing data on NSCLC patients with HER2 exon 20 mutations. Additional details will be available on Spectrum's website post-presentation.